Colin Stott

As Director of Research and Development Operations at GW Pharma, Colin was closely involved in the approval of Sativex®, GW’s first licensed cannabis-based product, and the more recently NDA-approved cannabinoid (CBD) medicine for treatment-resistant epilepsy, Epidiolex®. He was also a key individual in the development of GW’s discovery and development pipeline, until 2017. As Scientific Affairs Director, he was part of the Medical Affairs team responsible for the preparation for launch of Epidyolex® in the international region (ex-US). Colin has more than 30 years’ experience in preclinical & clinical development with specific expertise in the development of botanical medicines, particularly cannabinoid / cannabis-based medicines. He is now COO of Alterola Biotech / Abti.